

## SEARCH REQUEST FORM

Requestor's Name: \_\_\_\_\_ Serial Number: \_\_\_\_\_

Date: \_\_\_\_\_ Phone: \_\_\_\_\_ Art Unit: \_\_\_\_\_

### Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

### STAFF USE ONLY

Date completed: 12/24/58

Searcher: cm

Terminal time: 10

Elapsed time: \_\_\_\_\_

CPU time: \_\_\_\_\_

Total time: 10

Number of Searches: 1

Number of Databases: U

#### Search Site

\_\_\_\_\_ STIC

☒ CM-1

\_\_\_\_\_ Pre-S

#### Type of Search

☒ N.A. Sequence X1

☒ A.A. Sequence X1

\_\_\_\_\_ Structure

\_\_\_\_\_ Bibliographic

#### Vendors

☒ IG MRP

\_\_\_\_\_ STN

\_\_\_\_\_ Dialog

\_\_\_\_\_ APS

\_\_\_\_\_ Geninfo

\_\_\_\_\_ SDC

\_\_\_\_\_ DARC/Questel

\_\_\_\_\_ Other

1. 5,770,704, Jun. 23, 1998, Receptor activation with inactive hepatocyte growth factor ligands; **Paul J. Godowski**, 530/402; 424/194.1, 195.11; 530/399 [IMAGE AVAILABLE]
2. 5,766,863, Jun. 16, 1998, Kinase receptor activation assay; **Paul J. Godowski**, et al., 435/7.21, 6, 7.4, 7.94, 69.1, 975; 436/501, 518, 531, 548; 530/388.22, 388.26, 389.6, 391.3 [IMAGE AVAILABLE]
3. 5,763,584, Jun. 9, 1998, Receptor activation with hepatocyte growth factor agonists; **Paul J. Godowski**, 530/402; 424/194.1, 195.11; 530/399 [IMAGE AVAILABLE]
4. 5,709,858, Jan. 20, 1998, Antibodies specific for Rse receptor protein tyrosine kinase; **Paul J. Godowski**, et al., 424/143.1, 139.1; 435/7.4; 530/387.3, 387.9, 388.22, 391.1, 391.3 [IMAGE AVAILABLE]
5. 5,696,086, Dec. 9, 1997, Methods and kits using macrophage stimulating protein; Hava Karsenty Avraham, et al., 514/12; 530/351, 380 [IMAGE AVAILABLE]
6. 5,684,136, Nov. 4, 1997, Chimeric hepatocyte growth factor (HGF) ligand variants; **Paul J. Godowski**, 530/399, 387.3 [IMAGE AVAILABLE]
7. 5,580,963, Dec. 3, 1996, Single-chain hepatocyte growth factor variants; **Paul J. Godowski**, et al., 530/399 [IMAGE AVAILABLE]
8. 5,547,856, Aug. 20, 1996, Hepatocyte growth factor variants; **Paul J. Godowski**, et al., 435/69.4, 320.1, 325; 530/399; 536/23.51 [IMAGE AVAILABLE]
9. 5,328,837, Jul. 12, 1994, Hepatocyte growth factor protease domain variants; **Paul J. Godowski**, et al., 435/69.4; 530/399; 536/23.51 [IMAGE AVAILABLE]
10. 5,316,921, May 31, 1994, Single-chain hepatocyte growth factor variants; **Paul J. Godowski**, et al., 435/69.4; 530/399; 536/23.51 [IMAGE AVAILABLE]

=> d his

(FILE 'USPAT' ENTERED AT 10:10:32 ON 31 DEC 1998)

L1	1 S (TIE LIGAND?)/TI
L2	1 S (TIE LIGAND?)/AB
	E GODOWSKI, P/IN
L3	10 S E4
	E GURNEY, AU/IN

RESULT 1

ID R94605 standard; Protein; 496 AA.  
 AC R94605;  
 DT 28-OCT-1996 (first entry)  
 DE Human TIE-2 ligand 2 derived from pBluescript KS clone.  
 KW Angiogenesis; neovascularisation; tumour development; wound healing;  
 KW TIE; tyrosine kinase with Ig and EGF homology domains; vector;  
 KW recombinant; clone; diagnosis; ischaemia; thromboembolytic disease;  
 KW atherosclerosis; inflammation; diabetes; ligand bodies; delivery;  
 KW targeting.  
 OS Homo sapiens.  
 PN WO9611269-A2.  
 PD 18-APR-1996.  
 PF 06-OCT-1995; U12935.  
 PR 07-OCT-1994; US-319932.  
 PR 27-OCT-1994; US-330261.  
 PR 02-DEC-1994; US-348492.  
 PR 09-DEC-1994; US-353503.  
 PR 17-JAN-1995; US-373579.  
 PR 06-APR-1995; US-418595.  
 PA (REGE-) REGENERON PHARM INC.  
 PI Aldrich TH, Bruno J, Davis S, Goldfarb M, Jones PF;  
 PI Maisonnier PC, Radziejewski C, Yancopoulos GD;  
 DR WPI; 96-209850/21.  
 DR N-PSDB; T14650.  
 PT Nucleic acid encoding TIE-2 ligand and related vectors - useful in  
 PT diagnosis and treatment of neovascularisation, tumours, etc., or to  
 PT promote wound healing, etc.  
 PS Claim 2; Fig 6; 84pp; English.  
 CC R94605 is a human TIE-2 (hTIE-2) ligand 2 derived from a pBluescript  
 CC KS clone. hTIE-2 ligand DNAs of the invention are recombinant versions  
 CC of the native ligand coding sequences and may be used to produce the  
 CC ligands at a high yield. Antibodies and receptor bodies that bind to  
 CC TIE-2 ligands may be used to inhibit angiogenesis and neovascularisation  
 CC (e.g. associated with tumour development) and the TIE-2 ligands  
 CC themselves are useful to promote neovascularisation and wound healing  
 CC e.g. for treatment of ischaemia. TIE-2 ligands are also useful to  
 CC treat thromboembolytic disease, atherosclerosis, inflammation and  
 CC diabetes. Ligand bodies contg. TIE-2 ligands may also be useful for  
 CC the delivery and targeting of growth factors, toxins etc. to sites  
 CC where their presence is advantageous.  
 SQ Sequence 496 AA;

Query Match 18.5%; Score 688; DB 18; Length 496;  
 Best Local Similarity 30.8%; Pred. No. 6.64e-48;  
 Matches 129; Conservative 99; Mismatches 174; Indels 17; Gaps 16;

Db 84 enimenntqwlmklenyiqdnmk-kemveiqqnavqngtvmieigtnllnqtaeqtrkl 142  
 |::|| : || : :| | :| | : : : :| : | : : : :  
 Qy 77 EVLLENRVH-KQELELLNNELLKQKRQIETLQQLVEVDGGIVSEV-KLLRKESRNMNSRV 134  
 Db 143 tdveaqvlnqttrlelqllehslnstnklekqildqtseinklqdknsflekkvlamedkh 202  
 |:: |::| : : : :| : ||::||::||::| | | | :  
 Qy 135 TQLYMQLLHEIIR-K-R--DNALELSQLENRILNQTADMLQLASKYKDLEHKYQHLATLA 190  
 Db 203 iiqlqsikeekdqlq-vlvskqnsiieelek-kivtatvnnsvl-qkqqhdlmetvn-nl 258  
 | : | : : : | | : : : : : : : | : : | : : : | : :  
 Qy 191 HNQSEIIAQLEEHCRVPSARVPVQPPPAAPPRVYQPPTYNRIINQISTNEIQSDQNLKV 250  
 Db 259 ltm-mstsnsakd-ptvakeeqisfrdcaevfksghhttngiytltpfnsteeik-aycdm 315  
 | : : | : : : : ||| : : || |::|| | |::| : : ||

Qy 251 LPPPLPTMPTLTSLPSSTDKPSGPWRDCLQALEDGHDTSSIIY-LVKPENTNRLMQVWCDQ 309

Db 316 eaggggwtiiqrredgsxdfqrtwkeykvfgnpsgeywlgnfvsqldnqqryvlkihl 375  
| | | | : | | | | | | | | | | | | | | : | | | | | | : :

Qy 310 RHDPGGWTVIQRRLDGSVNFFRNWETKYQGFGNIDGEYWLGLENIYWLTNQGNKLLVTM 369

Db 376 kdwegneayslyehfylsseelnyrihlkgltgtagkissisqpgndfstkdgdndkcic 435  
| | | : : | | | : | | : : | | | : | : : | | | : |

Qy 370 EDWSGRKVFAEYASFRLEPESEYYKLRLGRYHGNAGD-SFTWHNGKQFTTLDRDHDVYTG 428

Db 436 kcsqmltggwwfdacgpsnlngmyypqrqntnkf-ngikwyywkgsgyslkattmmirp 493  
: | : : | | | : : | | : | | : : : | : : | | | | | | |

Qy 429 NCAHYQKGGWWYNACAHSNLNGVWYRGGHYRSRYQDGVYWAEFRGGSYSLKKVVMIRP 487